Vis enkel innførsel

dc.contributor.authorChemaly, Melody
dc.contributor.authorMarlevi, David
dc.contributor.authorIglesias, Maria Jesus
dc.contributor.authorLengquist, Mariette
dc.contributor.authorKronqvist, Malin
dc.contributor.authorBos, Daniel
dc.contributor.authorvan Dam-Nolen, Dianne H. K.
dc.contributor.authorvan der Kolk, Anja
dc.contributor.authorHendrikse, Jeroen
dc.contributor.authorKassem, Mohamed
dc.contributor.authorMatic, Ljubica
dc.contributor.authorOdeberg, Jacob
dc.contributor.authorde Vries, Margreet R.
dc.contributor.authorKooi, M. Eline
dc.contributor.authorHedin, Ulf
dc.date.accessioned2023-09-06T12:20:46Z
dc.date.available2023-09-06T12:20:46Z
dc.date.issued2023-05-24
dc.description.abstractBackground: Intraplaque hemorrhage (IPH) is a hallmark of atherosclerotic plaque instability. Biliverdin reductase B (BLVRB) is enriched in plasma and plaques from patients with symptomatic carotid atherosclerosis and functionally associated with IPH. Objective: We explored the biomarker potential of plasma BLVRB through (1) its correlation with IPH in carotid plaques assessed by magnetic resonance imaging (MRI), and with recurrent ischemic stroke, and (2) its use for monitoring pharmacotherapy targeting IPH in a preclinical setting. Methods: Plasma BLVRB levels were measured in patients with symptomatic carotid atherosclerosis from the PARISK study (n = 177, 5 year follow-up) with and without IPH as indicated by MRI. Plasma BLVRB levels were also measured in a mouse vein graft model of IPH at baseline and following antiangiogenic therapy targeting vascular endothelial growth factor receptor 2 (VEGFR-2). Results: Plasma BLVRB levels were significantly higher in patients with IPH (737.32 ± 693.21 vs. 520.94 ± 499.43 mean fluorescent intensity (MFI), p = 0.033), but had no association with baseline clinical and biological parameters. Plasma BLVRB levels were also significantly higher in patients who developed recurrent ischemic stroke (1099.34 ± 928.49 vs. 582.07 ± 545.34 MFI, HR = 1.600, CI [1.092–2.344]; p = 0.016). Plasma BLVRB levels were significantly reduced following prevention of IPH by anti-VEGFR-2 therapy in mouse vein grafts (1189 ± 258.73 vs. 1752 ± 366.84 MFI; p = 0.004). Conclusions: Plasma BLVRB was associated with IPH and increased risk of recurrent ischemic stroke in patients with symptomatic low- to moderate-grade carotid stenosis, indicating the capacity to monitor the efficacy of IPH-preventive pharmacotherapy in an animal model. Together, these results suggest the utility of plasma BLVRB as a biomarker for atherosclerotic plaque instability.en_US
dc.identifier.citationChemaly, Marlevi, Iglesias, Lengquist, Kronqvist, Bos, van Dam-Nolen, van der Kolk, Hendrikse, Kassem, Matic, Odeberg, de Vries, Kooi, Hedin. Biliverdin Reductase B Is a Plasma Biomarker for Intraplaque Hemorrhage and a Predictor of Ischemic Stroke in Patients with Symptomatic Carotid Atherosclerosis. Biomolecules. 2023;13(6)en_US
dc.identifier.cristinIDFRIDAID 2169765
dc.identifier.doi10.3390/biom13060882
dc.identifier.issn2218-273X
dc.identifier.urihttps://hdl.handle.net/10037/30754
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.journalBiomolecules
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleBiliverdin Reductase B Is a Plasma Biomarker for Intraplaque Hemorrhage and a Predictor of Ischemic Stroke in Patients with Symptomatic Carotid Atherosclerosisen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution 4.0 International (CC BY 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution 4.0 International (CC BY 4.0)